[1]浦飞飞 陈凤霞 邵增务△ 杨佳铭 张志才 刘建湘.程序性死亡因子配体1在骨肉瘤中的表达及临床病理学意义[J].中国中医骨伤科杂志,2022,30(05):6-10.
　PU Feifei CHEN Fengxia SHAO Zengwu YANG JiamingZHANG Zhicai LIU Jianxiang.Programmed Cell Death Ligand-1(PD-L1)Expression inOsteosarcoma and Its Clinicopathological Values[J].Chinese Journal of Traditional Medical Traumatology & Orthopedics,2022,30(05):6-10.
点击复制

程序性死亡因子配体1在骨肉瘤中的表达及临床病理学意义()
分享到：

《中国中医骨伤科杂志》[ISSN:1005-0205/CN:42-1340/R]

卷:
第30卷
期数:
2022年05期
页码:
6-10
栏目:
临床研究
出版日期:
2022-05-15

文章信息/Info

Title:
Programmed Cell Death Ligand-1(PD-L1)Expression inOsteosarcoma and Its Clinicopathological Values
文章编号:
1005-0205(2022)05-0006-05
作者:
浦飞飞1 陈凤霞2 邵增务1△ 杨佳铭1 张志才1 刘建湘1
1华中科技大学同济医学院附属协和医院骨科(武汉,430022)
2武汉大学中南医院肿瘤放化疗科
Author(s):
PU Feifei1 CHEN Fengxia2 SHAO Zengwu1△ YANG Jiaming1ZHANG Zhicai1 LIU Jianxiang1
1Department of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China; 2Department of Radiation Oncology and Medical Oncology, Zhongnan Hospital, Wuhan University, Wuhan 430071, China.
关键词:
程序性死亡因子1; 程序性死亡因子配体1; 骨肉瘤; 生存分析; 预后
Keywords:
programmed cell death factor 1(PD-1);  programmed cell death ligand-1(PD-L1);  osteosarcoma;  survival analysis;  prognosis
分类号:
R738.1
文献标志码:
A
摘要:
目的:探讨程序性死亡因子配体1(PD-L1)在骨肉瘤细胞和组织中的表达及对患者预后的影响。方法:采用Western Blot检测PD-L1在骨肉瘤细胞系和成骨细胞系中的表达,并用免疫组织化学(IHC)方法检测肿瘤及癌旁组织中PD-L1的表达,用Kaplan-Meier法进行生存分析。结果:PD-L1在骨肉瘤细胞株中的表达高于正常成骨细胞,而且其在骨肉瘤组织中的表达也显著高于癌旁组织,差异有统计学意义(P<0.05)。Kaplan-Meier生存分析显示PD-L1高表达患者预后较低表达患者差,差异有统计学意义(P<0.05)。结论:PD-L1在骨肉瘤中高表达,其高表达与患者预后不良有关,提示PD-L1可作为潜在的治疗靶点。
Abstract:
To investigate the prognostic value of the programmed cell death ligand-1(PD-L1)expression in osteosarcoma cells and tissues. Methods: Western Blot was used to detect the expression of PD-L1 in osteosarcoma cells and osteoblast cell line. Immunohistochemical(IHC)method was used to detect the expression of PD-L1 in tumors and adjacent tissues. Survival analysis was conducted by Kaplan-Meier analysis. Results:The expression of PD-L1 in osteosarcoma cell lines was higher than that in osteoblast cell line, and the expression of PD-L1 in osteosarcoma tissues was significantly higher than that in the adjacent tissues(P<0.05). Kaplan-Meier survival analysis showed that patients with high PD-L1 expression had a worse prognosis than those with low expression(P<0.05). Conclusion:PD-L1 is highly expressed in osteosarcoma, which is associated with poor prognosis of patients, suggesting that it may be a potential therapeutic target.

参考文献/References:

[1] 浦飞飞,邵增务.骨肉瘤基因治疗研究进展[J].国际骨科学杂志,2013,34(3):193-195.
[2] 浦飞飞,张志才,邵增务,等.骨水泥型与非骨水泥型假体置换治疗膝关节周围骨肉瘤的疗效评价[J].中国骨与关节杂志,2021,10(2):107-110.
[3] 浦飞飞,邵增务.T淋巴细胞免疫球蛋白黏蛋白-3在肿瘤免疫中的研究进展[J].肿瘤防治研究,2017,44(10):701-705.
[4] CHEN S,GUENTHER L M,ARONHALT A,et al.PD-1 and PD-L1 expression in osteosarcoma:which specimen to evaluate?[J].J Pediatr Hematol Oncol,2020,42(8):482-487.
[5] ZHANG M L,CHEN L,LI Y J,et al.PD-L1/PD-1 axis serves an important role in natural killer cell induced cytotoxicity in osteosarcoma[J].Oncol Rep,2019,42(5):2049-2056.
[6] PU F,CHEN F,ZHANG Z,et al.TIM-3 expression and its association with overall survival in primary osteosarcoma[J].Oncol Lett,2019,18(5):5294-5300.
[7] SINKOVICS J G,HORVATH J C.Evidence accumulating in support of cancer vaccines combined with chemotherapy:a pragmatic review of past and present efforts[J].Int J Oncol,2006,29(4):765-777.
[8] DAI S,JIA R,ZHANG X,et al.The PD-1/PD-Ls pathway and autoimmune diseases[J].Cell Immunol,2014,290(1):72-79.
[9] CHENG X,VEVERKA V,RADHAKRISHNAN A,et al.Structure and interactions of the human programmed cell death 1 receptor[J].J Biol Chem,2013,288(17):11771-11785.
[10] 王平,杨文秀,周杰.弥漫大B细胞淋巴瘤组织PD-1/PD-L1与C-myc和Bcl-2表达相关性研究[J].中华肿瘤防治杂志,2020,27(14):1151-1156.
[11] 赵宇飞.PD1/PDL1抑制剂治疗肿瘤[J].中国肿瘤生物治疗杂志,2020,24(8):904-911.
[12] SUNSHINE J,TAUBE J M.PD-1/PD-L1 inhibitors[J].Curr Opin Pharmacol,2015,23:32-38.
[13] 卢俊米,冯娟,郑红梅,等.PD-L1 在非小细胞肺癌中表达的临床意义[J].中南大学学报(医学版),2020,45(10):1149-1154.
[14] LIN H,WEI S,HURT E M,et al.Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression[J].J Clin Invest,2018,128(2):805-815.
[15] CHOU A J,GELLER D S,GORLICK R.Therapy for osteosarcoma:where do we go from here?[J].Paediatr Drugs,2008,10(5):315-327.
[16] KOIRALA P,ROTH M E,GILL J,et al.Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma[J].Sci Rep,2016,6:30093.
[17] LUSSIER D M,JOHNSON J L,HINGORANI P,et al.Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma[J].J Immunother Cancer,2015,3:21.
[18] WANG J,HU C,WANG J,et al.Checkpoint blockade in combination with doxorubicin augments tumor cell apoptosis in osteosarcoma[J].J Immunother,2019,42(9):321-330.

备注/Memo

备注/Memo:
基金项目:国家自然科学基金项目(81904231)
中国博士后科学基金项目(2020M672369)
△通信作者 E-mail:shaozengwupro@163.com
更新日期/Last Update: 1900-01-01